Article

The New York Times on 2024-03-08 15:18

FDA delays action on closely watched Alzheimer’s drug

The decision is likely to surprise many Alzheimer’s experts, doctors and patients who had expected the medication would soon be on the market.

Related news

FDA delays action on promising Alzheimer’s drug donanemab, drugmaker Eli Lilly says USA today
F.D.A. Delays Action on Closely Watched Alzheimer’s Drug The New York Times
Why next week's Alzheimer’s drug trial results from Biogen will be closely watched bizjournals.com
Washington
FDA delays action of Egalet's abuse-deterrent pain medicine bizjournals.com
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDA Forbes
Indianapolis
TFDA Approves Alzheimer’s Medication today.uconn.edu
Encarnación de Díaz
FFDA approves Biogen Alzheimer’s drug ft.com
MFDA approves Eli Lilly Alzheimer’s drug donanemab mvtelegraph.com
Japan , Indiana , Indianapolis
FDA conditionally approves controversial Alzheimer’s drug The Hindu
Phase 4 , Japan , Massachusetts , Cambridge
Panels find FDA, Biogen rushed Alzheimer’s drug nwaonline.com
Philadelphia , Cambridge
HFDA Approves Much-Debated Alzheimer’s Drug hamodia.com
Japan , Cambridge
FDA approves Biogen’s controversial Alzheimer’s drug New York Post
Phoenix , Massachusetts , Cambridge
Eli Lilly applies for FDA approval on Alzheimer’s drug Arkansas Online
Rochester , San Francisco , New York , Amsterdam , Indianapolis
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Forbes
FDA OKs Alzheimer’s drug that modestly slows disease San Jose Mercury News
Japan
FDA approves second Alzheimer’s drug that can modestly slow disease Shropshire Star
Saint Louis , Japan
Lilly shares slip as FDA seeks more Alzheimer’s drug data seattletimes.com
Japan